RU2019115913A3 - - Google Patents

Download PDF

Info

Publication number
RU2019115913A3
RU2019115913A3 RU2019115913A RU2019115913A RU2019115913A3 RU 2019115913 A3 RU2019115913 A3 RU 2019115913A3 RU 2019115913 A RU2019115913 A RU 2019115913A RU 2019115913 A RU2019115913 A RU 2019115913A RU 2019115913 A3 RU2019115913 A3 RU 2019115913A3
Authority
RU
Russia
Application number
RU2019115913A
Other languages
Russian (ru)
Other versions
RU2019115913A (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of RU2019115913A publication Critical patent/RU2019115913A/ru
Publication of RU2019115913A3 publication Critical patent/RU2019115913A3/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
RU2019115913A 2016-12-05 2017-12-05 Природные комбинированные гормонозаместительные составы и способы терапии RU2019115913A (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662430339P 2016-12-05 2016-12-05
US62/430,339 2016-12-05
US201762481060P 2017-04-03 2017-04-03
US62/481,060 2017-04-03
PCT/US2017/064788 WO2018136161A1 (en) 2016-12-05 2017-12-05 Natural combination hormone replacement formulations and therapies

Publications (2)

Publication Number Publication Date
RU2019115913A RU2019115913A (ru) 2021-01-15
RU2019115913A3 true RU2019115913A3 (cg-RX-API-DMAC7.html) 2021-03-19

Family

ID=62908279

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2019115913A RU2019115913A (ru) 2016-12-05 2017-12-05 Природные комбинированные гормонозаместительные составы и способы терапии

Country Status (11)

Country Link
EP (1) EP3548036A4 (cg-RX-API-DMAC7.html)
JP (1) JP2020504093A (cg-RX-API-DMAC7.html)
KR (1) KR20200018383A (cg-RX-API-DMAC7.html)
CN (1) CN110290793A (cg-RX-API-DMAC7.html)
AU (1) AU2017394679A1 (cg-RX-API-DMAC7.html)
BR (1) BR112019011655A2 (cg-RX-API-DMAC7.html)
CA (1) CA3045024A1 (cg-RX-API-DMAC7.html)
IL (1) IL267023A (cg-RX-API-DMAC7.html)
MX (1) MX2019006513A (cg-RX-API-DMAC7.html)
RU (1) RU2019115913A (cg-RX-API-DMAC7.html)
WO (1) WO2018136161A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220105107A1 (en) * 2020-10-01 2022-04-07 Michael Liguori Bioidentical progesterone cream infused with nanoemulsified cbd
GB202316026D0 (en) * 2023-10-19 2023-12-06 Theramex Hq Uk Ltd Methods of prevention or treatment

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5208225A (en) * 1986-02-27 1993-05-04 Warner-Lambert Company Compositions containing fixed combinations
US20020132801A1 (en) * 2001-01-11 2002-09-19 Schering Aktiengesellschaft Drospirenone for hormone replacement therapy
US6901278B1 (en) * 2002-01-29 2005-05-31 Morris Notelovitz Methods for reducing the risk of breast cancer in and improving the health of women
US20040062794A1 (en) * 2002-09-30 2004-04-01 Lee Shulman 17Beta- estradiol/levonorgestrel transdermal patch for hormone replacement therapy
US9301920B2 (en) * 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
AR100562A1 (es) * 2014-05-22 2016-10-12 Therapeuticsmd Inc Composición farmacéutica de estradiol y progesterona para terapia de reemplazo hormonal

Also Published As

Publication number Publication date
IL267023A (en) 2019-07-31
RU2019115913A (ru) 2021-01-15
AU2017394679A1 (en) 2019-06-13
WO2018136161A1 (en) 2018-07-26
WO2018136161A9 (en) 2019-08-22
EP3548036A4 (en) 2020-06-17
KR20200018383A (ko) 2020-02-19
MX2019006513A (es) 2019-08-14
JP2020504093A (ja) 2020-02-06
CN110290793A (zh) 2019-09-27
BR112019011655A2 (pt) 2019-10-22
EP3548036A1 (en) 2019-10-09
CA3045024A1 (en) 2018-07-26

Similar Documents

Publication Publication Date Title
BR122021017409A2 (cg-RX-API-DMAC7.html)
BR112019002665A2 (cg-RX-API-DMAC7.html)
BR112018004986A2 (cg-RX-API-DMAC7.html)
BR112019001429A2 (cg-RX-API-DMAC7.html)
BR112019008315A2 (cg-RX-API-DMAC7.html)
BR212018070320U2 (cg-RX-API-DMAC7.html)
BR112019008501B1 (pt) Método realizado por um equipamento de usuário, método realizado por um nó de rede, equipamento de usuário, nó de rede, e, meios de armazenamento legíveis por computador
BR112019003116B1 (pt) Configuração de símbolo de rajada comum de uplink
BR112019002832B1 (pt) Método de transmissão de informação e dispositivo de terminal
BR112019002215B1 (pt) Seleção de nível de melhoramento de cobertura baseada em classe de potência
BR112018076493B1 (pt) Sistemas e métodos para detecção de posição de feixe de luz
BR112018073794B1 (pt) Partícula, método de geração da partícula, vacina ou composição farmacêutica
BR122026002520A2 (pt) Célula, conjunto de vetores para expressar uma proteína de ligação a antígeno biespecífica em uma célula, conjunto de vetores, sistema, método, e, método para produção de uma proteína de ligação a antígeno
BR112019006736A2 (cg-RX-API-DMAC7.html)
CN303632805S (zh) 包装瓶(2.0花茶450ml高瓶2015)
CN303639995S (zh) T型吊带式行车
CN303579321S (zh) 波导阵列天线
CN303570959S (zh) 油桶
CN303575245S (zh) 3d装饰膜(起伏)
CN303576959S (zh) 瓶(酒)
CN303536045S (zh) 嫁衣(15)
CN303536110S (zh) 眼罩(花纹)
CN303536111S (zh) 眼罩(条纹)
CN303549203S (zh) 包装盒(习酒酱香壹号)
CN303536278S (zh) 高帮爵士靴

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20220405